|
Post by nylefty on Jul 15, 2019 18:11:07 GMT -5
On StockTwits somebody has posted a listing for Fiasp on the GoodRx website. Right above the GoodRx Fiasp listing is an Afrezza ad. That's targeted advertising!
|
|
|
Post by peppy on Jul 15, 2019 18:18:52 GMT -5
On StockTwits somebody has posted a listing for Fiasp on the GoodRx website. Right above the GoodRx Fiasp listing is an Afrezza ad. That's targeted advertising! and then you go to the site, and see the price of the titration pack is $1000.
|
|
|
Post by nylefty on Jul 15, 2019 19:06:52 GMT -5
On StockTwits somebody has posted a listing for Fiasp on the GoodRx website. Right above the GoodRx Fiasp listing is an Afrezza ad. That's targeted advertising! and then you go to the site, and see the price of the titration pack is $1000. But you also see an Afrezza ad for the $15 copay and between the price listings for Kroger and RiteAid there's a note from GoodRx about the $15 copay.
|
|
|
Post by rockstarrick on Jul 15, 2019 20:35:28 GMT -5
It is about dose also.. as RAA and Afrezza aren't the same unit for unit as was stated initially and this was how the trials were ran for approval.. it amazes me that we ever got approval in the first place. You need at least 1.5 or 2Xs Afrezza compared to RAA.. everything about this was botched from the beginning..we needed superiority trials.. instead we ended up noninferior.. and don't have the cash .. It's all a mess.. and we are running out of time.. those who can't see this are blind. To continue with the same marketing will not work.. the climb up will be slow.. in business that's not a good thing.. So the solution is partner with large BP or think out of the box.. I hate to say it because I know how some feel around here.. but Vdex is a solution.. And I havent resorted to slamming MC.. I'm just saying his marketing isn't working and this Goodrx deal is another example of doing the same old thing that isn't going to work unless underlying problems are solved first. Definitely true, almost everything in the beginning, that was happening with regards to Marketing and ”Using” afrezza, was questionable, to put it lightly.
|
|
|
Post by radgray68 on Jul 15, 2019 21:36:42 GMT -5
It is about dose also.. as RAA and Afrezza aren't the same unit for unit as was stated initially and this was how the trials were ran for approval.. it amazes me that we ever got approval in the first place. You need at least 1.5 or 2Xs Afrezza compared to RAA.. everything about this was botched from the beginning..we needed superiority trials.. instead we ended up noninferior.. and don't have the cash .. It's all a mess.. and we are running out of time.. those who can't see this are blind. To continue with the same marketing will not work.. the climb up will be slow.. in business that's not a good thing.. So the solution is partner with large BP or think out of the box.. I hate to say it because I know how some feel around here.. but Vdex is a solution.. And I havent resorted to slamming MC.. I'm just saying his marketing isn't working and this Goodrx deal is another example of doing the same old thing that isn't going to work unless underlying problems are solved first. Definitely true, almost everything in the beginning, that was happening with regards to Marketing and ”Using” afrezza, was questionable, to put it lightly. The whole dosing fiasco(yes, Al and Hakan should have sorted this stuff out before launching) has only just been resolved in the more recent trials. Finally, now we have a teachable, simple way to titrate Afrezza that is backed up by real life clinical data, not a super secret method that can only be replicated by some diabetes outfit nobody's heard of with only a few locations to speak of. Nobody gives Mike credit fo r NOT blowing the entire $40 million on the 1st quarter advertising campaign. Knowing the difficulties in changing minds, and knowing the preciousness of the cash we were spending, he carefully did some targeted ads, some national ads, he did some testing of markets by turning it on and then off to see the effects. This guy, for a young executive in his first large ad buy, showed really good restraint and stopped the spending as soon as it could be discernible that it wasn't having the desired effect. Many have bashed the commercial. I thought it was just o.k. myself. But, recently Mike even mentioned that they will look at perhaps a new commercial, if needed. That showed a truthfulness beyond the required, in my mind. He's on top of it but he's steering a cruise ship, not a speed boat.
|
|
|
Post by sportsrancho on Jul 16, 2019 7:03:40 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 16, 2019 7:45:52 GMT -5
That should have been done FIRST, way before wasting millions on the TV advertising with stupid ads. I keep saying that it costs 30c to keep a client and 3$ to add a new one. But these multi-million dollar salary people don't give a hoot about what makes sense and stick to what other multi billion dollar huge pharmas do. Last I checked we are not and we have to be flexible and nimble and wasting precious dollars on such employees and strategies is not helpful at all. Not necessarily. It depends on the terms of their debt deal. Some deals are not callable which means it has to run the term. Maybe they couldn't get a good deal back then? Timing is everything. Now we're at the inflection point when that bad deal behind us and MNKD is in the position to shop their new deal. I believe they will refi all debt and just have 1 deal plus capital on much favorable terms with a long expiration date. And then finally the restrictive covenants will be lifted and MNKD can act like the Global Pharmaceutical Company that they have become under Mike's leadership. I also believe that the TV Ads were successful. It will not translate into quick sales because most diabetics don't jump at the new treatments. They will inquire about Afrezza at their next doctor visit and go from there. But at least they are aware and their Doctor is aware now. Hopefully the TREND SETTERS (those who love new treatments) would have gone to their doctors and asked them about Afrezza. All we know is that SALES are RISING, MNKD is using less capital on a quarterly basis and PROGRESS is continuing.
|
|
|
Post by helmut8056 on Jul 16, 2019 8:31:59 GMT -5
The sun is shining! Every thing is beautiful! Don't change or do anything! Please ignore Sports' reality check above ……
|
|
|
Post by rockstarrick on Jul 16, 2019 9:58:21 GMT -5
Definitely true, almost everything in the beginning, that was happening with regards to Marketing and ”Using” afrezza, was questionable, to put it lightly. The whole dosing fiasco(yes, Al and Hakan should have sorted this stuff out before launching) has only just been resolved in the more recent trials. Finally, now we have a teachable, simple way to titrate Afrezza that is backed up by real life clinical data, not a super secret method that can only be replicated by some diabetes outfit nobody's heard of with only a few locations to speak of. Nobody gives Mike credit fo r NOT blowing the entire $40 million on the 1st quarter advertising campaign. Knowing the difficulties in changing minds, and knowing the preciousness of the cash we were spending, he carefully did some targeted ads, some national ads, he did some testing of markets by turning it on and then off to see the effects. This guy, for a young executive in his first large ad buy, showed really good restraint and stopped the spending as soon as it could be discernible that it wasn't having the desired effect. Many have bashed the commercial. I thought it was just o.k. myself. But, recently Mike even mentioned that they will look at perhaps a new commercial, if needed. That showed a truthfulness beyond the required, in my mind. He's on top of it but he's steering a cruise ship, not a speed boat. ”The whole dosing fiasco(yes, Al and Hakan should have sorted this stuff out before launching) has only just been resolved in the more recent trials. Finally, now we have a teachable, simple way to titrate Afrezza that is backed up by real life clinical data, not a super secret method that can only be replicated by some diabetes outfit nobody's heard of with only a few locations to speak of.” If you are referring to VDEX here, and have the opinion that I believe they will save MNKD, then you've misunderstood me. While I have always appreciated VDEX, and the extra effort they have put out to try and help with retention, this recent public display of ”mutiny”, (for lack of a better word), has now forced MNKD investors to ”pick a side” in the battle between MNKD and VDEX. Like it or not, VDEX, for whatever reason, has divided MNKD investors, and as I always do, I respectfully pick MNKD. With regards to Mike, I believe MC has done well setting the MNKD dinner table, but now it's time to serve dinner. MNKD investors are hungry and fatigued from chewing on a bone with nearly no meat left on it. When MC gives us a little meat with our soup bone, I'm sure he will get all the support and credit he deserves. With all that said, I don't think this VDEX fiasco has done anything even remotely positive for MNKD, Afrezza, or VDEX, and because of the way VDEX, (for whatever reason), has tried to strong-arm MNKD into a deal, the possibility of MNKD and VDEX ever reaching common ground is near zero. Good Luck Everybody ✌🏻😎
|
|
|
Post by jonny80s on Jul 16, 2019 10:32:14 GMT -5
One more PR with some actual meat on the bone coupled with a decent couple of weeks scripts and we might see a run back to $2. Not going to hold my breath...
|
|
|
Post by sportsrancho on Jul 16, 2019 10:56:39 GMT -5
Since somebody brought up Vdex again, this “Civil War” thing in my opinion is stupid, we need as many scripts as possible ..work out a deal, some kind of deal. Get it done. Shake hands:-) Be on the side of Afrezza. If Mike and Bill decide on something that works, then I’m 100% behind it.. aren’t all you guys?! On second thought don’t answer that🤣🤷♀️
|
|
|
Post by mnholdem on Jul 16, 2019 11:13:51 GMT -5
Castagna and team need every tool at their disposal, IMO. V-December could be a tool to build awareness and to utilize in other ways (i.e. clinical/real world data) to advance Afrezza.
|
|
|
Post by thekindaguyiyam on Jul 16, 2019 11:46:43 GMT -5
Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients finance.yahoo.com/news/mannkind-partners-goodrx-help-raise-130000499.htmlMore than 65,000 patients pay over $200 per month for their mealtime insulin Commercially insured patients can pay as little as $15 per month for inhaled insulin Underinsured and uninsured patients can pay as little as $5 a day with MannKind direct purchase program WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin. This partnership will enable patients to find affordable treatment options and help raise awareness of Afrezza® (insulin human) Inhalation Powder as an alternative to injectable mealtime insulin. Afrezza is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. “Our partnership with GoodRx, whose mission is to help people find affordable and convenient healthcare, further enhances our efforts to help those whose lives depend on mealtime insulin. Coupled with our innovative direct purchase program and enhanced copay savings card programs, the GoodRx platform will allow us to potentially raise awareness about how patients can better manage the financial burden that comes with living with diabetes,” said Michael Castagna, Chief Executive Officer of MannKind. “We believe that Afrezza is an innovative therapeutic option and that price should not be a barrier to treatment.” “GoodRx is excited to partner with MannKind to help raise awareness on ways patients can save money on their mealtime insulin. We see partnerships with manufacturers as another way to continue to bring patients affordability options that can help them start and stay on therapy," said Jake Coniglio, Head of Manufacturer Solutions at GoodRx. Using the GoodRx platform, MannKind promotes a copay and savings card program which enables patients with commercial insurance to fill their prescription at their local pharmacy for as low as $15. The card, along with complete program details, can be downloaded at www.afrezzasavingscard.com. MannKind’s direct purchase cash program helps those with diabetes obtain the company’s inhaled insulin, Afrezza, for as little as $5 a day when people fill a 1-month supply. To participate in the direct purchase program, please register at www.insulinsavings.com to learn more information or gain access to attractive cash pricing for Afrezza. About Afrezza® Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com. About MannKind Corporation MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. About GoodRx GoodRx is America’s leading source of prescription and healthcare savings. More than 10 million people a month trust our free app and website to deliver the best prices at more than 70,000 pharmacies nationwide. Our discounts save Americans up to 80% on virtually all FDA-approved drugs and can be used by those with and without health insurance. Since 2011, GoodRx has helped Americans save more than $10 billion on their prescription drug expenses.
|
|
|
Post by rtmd on Jul 16, 2019 15:06:52 GMT -5
Has there been any word on how many have registered for the "insulinsavings" program?
|
|
|
Post by rockstarrick on Jul 16, 2019 15:58:10 GMT -5
Has there been any word on how many have registered for the "insulinsavings" program? 🐿😉😁😇
|
|